Over the last two decades, it has become evident that estrogens preserve the integrity of
energy homeostasis at central and peripheral levels. Estrogen deficiency, such as that …

Nuclear-and membrane-initiated estrogen signaling cooperate to orchestrate the pleiotropic
effects of estrogens. Classical estrogen receptors (ERs) act transcriptionally and govern the …

Recently, advances in molecular biology and bioinformatics have allowed a more thorough
understanding of tumorigenesis in aggressive PitNETs (pituitary neuroendocrine tumors) …

Despite most of the prolactinomas can be treated with endocrine therapy and/or surgery, a
significant percentage of these tumors can be resistant to endocrine treatments and/or recur …

Purpose Polycystic ovary syndrome (PCOS) and hyperprolactinemia are the most frequent
endocrine disorders in women which share several common features. There are …

Exploring the regulatory effects of estrogen on different body organs via its receptors is
largely of interest. Recently, the expression, signaling and the clinical significance of ERα36 …

Dopamine agonists (DAs) are preferred for the treatment of prolactinomas and are usually
very effective. Nonetheless, 20–30% of bromocriptine-and approximately 10% of …

Introduction Aggressive prolactinomas (APRLs) pose a significant clinical challenge due to
their high rate of regrowth and potentially life-threatening complications. In this study, we …

Prolactinomas (PRLomas) constitute approximately half of all pituitary adenomas and
approximately one-fifth of them are diagnosed in males. The clinical presentation of …

Prolactinomas are commonly treated with dopamine receptor agonists (DAs), such as
bromocriptine (BRC) and cabergoline (CAB). However, 10–30% of patients exhibit …